Security key
03969K108
Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT)
CUSIP: 03969K108
Q2 2020 13F Holders as of 30 Jun 2020
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 33,776,828
- Total 13F value
- $1,021,408,758
- Share change
- +1,093,678
- SEC-reported price per share
- $30.24
- Number of holders
- 55
- Value change
- +$33,104,690
- Number of buys
- 32
- Number of sells
- 14
- Shares outstanding
- 123,454,843
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2020
Institutions
55
Top holders
10
ARQT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2020
Previous quarter: Q1 2020
Arcutis Biotherapeutics, Inc. SEC filings
Arcutis Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03969K108
Recent filing periods:
Ownership snapshot
Top reported holders of ARQT - Arcutis Biotherapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FRAZIER MANAGEMENT LLC
Disclosed value leader
FRAZIER MANAGEMENT LLC
Comparable rows
15/15
Latest evidence
31 Mar 2020
13F
Lead comparable stake: 8.5%
Showing 1-6 of 15 holder rows.
Quick read
FRAZIER MANAGEMENT LLC leads the comparable SEC ownership view at 8.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FRAZIER MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
FRAZIER MANAGEMENT LLC
8.5%
FMR LLC
4.6%
ORBIMED ADVISORS LLC
3.8%
Bain Capital Life Sciences Invest...
3.2%
Vivo Capital, LLC
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FRAZIER MANAGEMENT LLC |
13F
Company
|
8.5%
|
$314,175,000
10,542,790 shares
|
— | 31 Mar 2020 |
| FMR LLC |
13F
Company
|
4.6%
|
$170,258,000
5,713,343 shares
|
— | 31 Mar 2020 |
| ORBIMED ADVISORS LLC |
13F
Company
|
3.8%
|
$139,281,000
4,673,850 shares
|
— | 31 Mar 2020 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
3.2%
|
$118,583,000
3,979,292 shares
|
— | 31 Mar 2020 |
| Vivo Capital, LLC |
13F
Company
|
1.4%
|
$50,259,000
1,686,527 shares
|
— | 31 Mar 2020 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
0.94%
|
$34,722,000
1,165,184 shares
|
— | 31 Mar 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
55
Shares
33,776,828
Rows available
55
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2020 vs Q1 2020 Across Filers
Q1 2020 holders
49
Q2 2020 holders
55
Holder diff
6
| Investor | Q1 2020 Shares | Q2 2020 Shares | Share Diff | Share Chg % | Q1 2020 value | Q2 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend